Growth Factor News and Research

RSS

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest.

17 Sep 2014

Urinary nerve growth factor shows diagnostic value

Urinary nerve growth factor could be a useful biomarker for the diagnosis of overactive bladder and a predictive biomarker to help guide treatment, Chinese researchers believe.

17 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

Growth factors present in human breast milk may protect against intestinal damage

Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology

10 Sep 2014

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived -mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.

4 Sep 2014

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

A new study published in the September issue of The FASEB Journal, identifies a novel strategy to diagnose the leading cause of blindness in adults, diabetic retinopathy, before irreversible structural damage has occurred.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

FK506 possesses a well-studied neuroregenerative effect, stimulating neurite extension in the presence of nerve growth factor in vitro, and enhancing nerve regeneration following nerve crush injury and isografting.

30 Aug 2014

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

28 Aug 2014

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.

28 Aug 2014

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

Reticular pseudodrusen predicts late-stage AMD

Reticular pseudodrusen increases the likelihood of people with choroidal neovascularisation in one eye also developing late-stage, age-related macular degeneration in the other eye, researchers report.

28 Aug 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Researchers find why certain glioblastomas become drug resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy.

26 Aug 2014

Growth Factor News and Research

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Ramucirumab effective second-line option for NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Urinary nerve growth factor shows diagnostic value

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Professor receives award for development of anti-angiogenic therapy for retinal disease

Growth factors present in human breast milk may protect against intestinal damage

Transplantation of B10 cells helps inhibit development of bladder fibrosis post SCI

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Mutant allele frequency predicts lung cancer TKI response

High PD-L1 expression linked to reduced survival in NSCLC

Reticular pseudodrusen predicts late-stage AMD

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Researchers find why certain glioblastomas become drug resistance

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News